A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS) Phase 2

Trial Profile

A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS) Phase 2

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Laquinimod (Primary)
  • Indications Multiple sclerosis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms ARPEGGIO
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 01 Dec 2017 According to an Active Biotech media release, Data from the trial will be presented at a future scientific conference and the full results will be published.
    • 01 Dec 2017 Primary endpoint has not been met. (Percent brain volume change (PBVC))
    • 28 Nov 2017 This trial has been completed in Germany (2017-10-01).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top